NLSP Wutah pendapatan triwulanan NLS Pharmaceutics

Simbol resmi perusahaan NLS Pharmaceutics Ltd. (NLSP)

NLS Pharmaceutics AG (NLSP) develops safe narcolepsy treatments without stimulant components. However, the research stage is causing a liquidity deficit and a need for loans. High margins during mass production and patents will ensure future growth. Quarterly revenue growth rates visualize sales dynamics, where the 0.00 mark records this indicator, helping to avoid purchasing the asset at its peak.

NLS Pharmaceutics AG (NLSP) - Tingkat wutah pendapatan sajrone kuartal saka 04.07.2022 nganti 31.10.2025

NLS Pharmaceutics AG - rincian analitis lan metrik utama (NLSP)

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis fundamental perusahaan:NLS Pharma - NLSP
Produk seri NLS Pharma

This indicator measures the dynamics of quarterly revenue changes, allowing investors to assess operational resilience and business scaling rates by comparing current revenues with the same period last year. Analyzing this quarterly revenue chart provides insight into the effectiveness of NLS Pharmaceutics AG (NLSP) and its seamless management of clinical trial outsourcing, where steady growth confirms the absence of operational disruptions when interacting with international CROs.